Pac-Link Management

Revance Therapeutics is a biopharmaceutical company focused on developing and commercializing products for dermatology and aesthetics. Its lead product, RT001, is a topical botulinum toxin type A for cosmetic use, hyperhidrosis treatment, and other dermatological indications.

Synerchip is a semiconductor company specializing in the development of high-speed digital interface technology designed for consumer electronics networks. Their primary focus is on enhancing home entertainment experiences by enabling simultaneous transmission of video, audio, and data. Synerchip's flagship product, Digital Interactive Interface for Video & Audio (DiiVA), facilitates seamless connectivity among various home electronic devices through a network that supports video, audio, USB, and Ethernet functionalities.

Revance Therapeutics is a biopharmaceutical company focused on developing and commercializing products for dermatology and aesthetics. Its lead product, RT001, is a topical botulinum toxin type A for cosmetic use, hyperhidrosis treatment, and other dermatological indications.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Broncus Technologies is a medical technology company specializing in minimally-invasive devices for treating emphysema and other lung diseases. Its flagship product, Exhale, employs Airway Bypass therapy, potentially the first minimally-invasive treatment for severe homogeneous emphysema. Broncus is currently enrolling patients worldwide in its pivotal EASE Trial.

Ultizen Games Ltd. is a game development and offshore outsourcing company based in Shanghai, China, founded in 2005. The company specializes in various aspects of game design, including level design, programming, art design, modeling, animation production, and testing services. Ultizen offers a range of products, including online casual games for PC, Xbox360 live arcade games, and the U-PAL online casual game platform. Additionally, the company provides a comprehensive suite of outsourcing services, such as art design, 2D and 3D art production, animation, porting, networking, testing, localization, and IPTV game development. Ultizen serves clients primarily in North America, Europe, and Japan, focusing on enhancing entertainment experiences while fostering creativity through its offerings.

Destinator Technologies, Inc. specializes in developing navigation software tailored for personal navigation devices and smartphones. The company provides software development kits that enable the creation of custom navigation solutions for both individual and corporate clients. Founded in 2003 as Homeland Security Technology Corporation, it rebranded to Destinator Technologies, Inc. in 2005. Headquartered in Richmond Hill, Canada, the company also maintains offices in the United States, Germany, Israel, Taiwan, and China. Destinator Technologies operates as a subsidiary of Intrinsyc Software International Inc.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Trellis Bioscience LLC is a biotechnology company focused on discovering and developing human antibody therapeutics for infectious diseases and oncology. The company utilizes its proprietary CellSpot technology platform to identify and extract rare, naturally optimized antibodies from healthy human donor blood cells. This enables the development of therapeutic monoclonal antibodies targeting various infectious diseases and cancer immune checkpoints. Trellis aims to offer alternatives for patients facing challenges with conventional protein therapeutics, particularly in cases where the immune system may attack these treatments. Founded in 1998, Trellis Bioscience is headquartered in Redwood City, California.

SunTen Phytotech Co., Ltd. is an herbal-based biotechnology company focused on creating botanical medicines and functional dietary products. The company develops a range of innovative products designed to address various medical needs. These include SB221, which combines traditional Chinese herbal extracts for the treatment and prevention of diseases related to vascular endothelial dysfunction; STA36, aimed at providing adjuvant treatment for chronic asthma; STD052, a partially purified herbal material targeting gastrointestinal, cardiovascular, and kidney issues; and STD06, an active component formulated for the treatment of skin disorders and wound healing. Through its herbal-based solutions, SunTen Phytotech seeks to enhance health outcomes and provide effective cures for a variety of conditions.

Broncus Technologies is a medical technology company specializing in minimally-invasive devices for treating emphysema and other lung diseases. Its flagship product, Exhale, employs Airway Bypass therapy, potentially the first minimally-invasive treatment for severe homogeneous emphysema. Broncus is currently enrolling patients worldwide in its pivotal EASE Trial.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Wavesat is a provider of advanced semiconductor solutions that cater to the needs of carrier and mobile device manufacturers focused on mobile broadband. The company is recognized for its innovative technologies, including the industry’s first WiMAX Forum Certified CPE design, which facilitates the deployment of a variety of broadband wireless technologies such as WiMAX Wave2, WiFi, and XG-PHS. Wavesat’s technology is built on an intelligent, multimode 4G architecture that supports seamless migration to future 4G technologies like LTE. By offering highly integrated and power-efficient broadband solutions, Wavesat enables mobile device manufacturers to optimize investments, reduce development time and risks, and accelerate their time-to-market. The company combines superior technical support with cost-effective platforms that include both software and reference designs, making it a key partner for businesses aiming to stay ahead in the rapidly evolving broadband landscape.

Polaris Networks is a provider of test tools, simulation tools, and software engineering services specifically designed for wireless and telecommunications technologies. The company develops optical transport switching systems that enhance communication capabilities. Its offerings include functional and load testers, as well as simulation tools tailored for LTE access and packet core networks. By supplying a diverse array of test tools and communication gateways, Polaris Networks serves network equipment manufacturers, service providers, and testing laboratories, enabling them to improve their operational efficiencies and communication infrastructures.

Symmetry Communications is creating the "Information Super Sky Way" of seamless global IP-based services for mobile wireless users. They are a leading provider of wireless packet data solutions for Internet and next-generation telecommunications services. Their packet data solutions enable wireless network operators to provide flexible service differentiation and new data services to market quicker than ever before.